Mostrar el registro sencillo del ítem

dc.contributor.authorGarcía, Elisa
dc.contributor.authorOchoa, Rodrigo
dc.contributor.authorVasquez, Isabel
dc.contributor.authorConesa Milián, Laura
dc.contributor.authorCarda, Miguel
dc.contributor.authorYepes, Andrés
dc.contributor.authorVélez, Iván D.
dc.contributor.authorRobledo, Sara M.
dc.contributor.authorCardona Galeano, Wilson Isidro
dc.date.accessioned2019-05-09T10:02:12Z
dc.date.available2019-05-09T10:02:12Z
dc.date.issued2019
dc.identifier.citationGarcía, E., Ochoa, R., Vásquez, I. et al. Med Chem Res (2019) 28: 608. https://doi.org/10.1007/s00044-019-02323-7ca_CA
dc.identifier.issn1054-2523
dc.identifier.issn1554-8120
dc.identifier.urihttp://hdl.handle.net/10234/182449
dc.description.abstractThe synthesis, antitrypanosomal, and cytotoxic activities of 17 furanchalcone derivatives are described herein. The structure of the synthesized products was elucidated by a combination of spectrometric analyses. The synthesized compounds were evaluated against Trypanosoma cruzi, which is the pathogenic species to humans. Cytotoxicity was evaluated against human U-937 macrophages. Eleven compounds were active against amastigotes of T. cruzi with EC50 values lower than 40 µM. Hybrids 7b–7d and 8a–8g showed better activity than benznidazole. Structure activity relationship (SAR) showed that the presence of electron withdrawing groups, such as nitro or fluorine, increased the activity and that the degree of oxygenation is essential for activity. In addition, molecular docking was used to identify a possible protein target for the designed compounds. A spearman correlation of 0.608 between the predicted scores and the experimental data profile the enzyme cruzipain as a potential candidate. Finally, in silico ADMET studies of the arylfuranchalcones showed that these novel compounds have suitable drug-like properties, making them potentially promising agents for antichagasic therapy.ca_CA
dc.format.extent30 p.ca_CA
dc.format.mimetypeapplication/pdfca_CA
dc.language.isoengca_CA
dc.publisherSpringer Verlagca_CA
dc.relation.isPartOfMedicinal Chemistry Research (2019) 28ca_CA
dc.rights© Springer Science+Business Media, LLC, part of Springer Nature 2019 “This is a post-peer-review, pre-copyedit version of an article published in Medicinal Chemistry Research. The final authenticated version is available online at: https://doi.org/10.1007/s00044-019-02323-7”ca_CA
dc.rights.urihttp://rightsstatements.org/vocab/InC/1.0/*
dc.subjectChagas diseaseca_CA
dc.subjectTrypanosoma cruzica_CA
dc.subjectFuranchalconeca_CA
dc.subjectHybridsca_CA
dc.subjectIn silico studiesca_CA
dc.subjectBiphenylca_CA
dc.titleFuranchalcone–biphenyl hybrids: synthesis, in silico studies, antitrypanosomal and cytotoxic activitiesca_CA
dc.typeinfo:eu-repo/semantics/articleca_CA
dc.identifier.doihttps://doi.org/10.1007/s00044-019-02323-7
dc.relation.projectIDCODI 6203ca_CA
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca_CA
dc.relation.publisherVersionhttps://link.springer.com/article/10.1007/s00044-019-02323-7ca_CA
dc.date.embargoEndDate2020-03-11
dc.type.versioninfo:eu-repo/semantics/acceptedVersionca_CA


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem